Protagonist Therapeutics: Leerink Partners assumes coverage with outperform rating; target price $190
PTGX•Leerink Partners assumed coverage of Protagonist Therapeutics with an outperform rating and a $190 target price.
Related News
ReAlpha says North Adams has Massachusetts’ lowest median home price at $245K in 2026 affordability study
AIRE•
American Financial Group: Wells Fargo cuts target price to $166 from $175
AFG•
UBS trims Wienerberger voting rights to 3.96% from 4.09%
UBS•
BMO cuts Prologis target price to $152 from $163
PLD•
Microsoft: Deutsche Bank raises target price to $600 from $550
MSFT•